TOP TEN perturbations for 390_at (Homo sapiens)

Organism: Homo sapiens
Gene: 390_at
Selected probe(set): 208376_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 390_at (208376_at) across 6674 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-3.727275
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-3.1346092
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%) / uninvolved skin sample (baseline)

Relative Expression (log2-ratio):2.323865
Number of Samples:6 / 5
Experimental ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%)
Punch biopsies of uninvolved skin obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25-cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control uninvolved skin sample (baseline)
Punch biopsies of uninvolved skin obtained from actinic keratosis (AK) patients before treatment (baseline). Samples were taken from cca 25 cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):1.7596941
Number of Samples:5 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

cutaneous T-cell lymphoma study 1 (plaque phase) / normal skin tissue

Relative Expression (log2-ratio):1.6791382
Number of Samples:7 / 8
Experimental cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):1.6538372
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):1.645647
Number of Samples:6 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 1 day treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the first topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

septic shock study 3 (D3; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-1.4565296
Number of Samples:9 / 22
Experimental septic shock study 3 (D3; non-survivor)
Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D2; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-1.4508181
Number of Samples:8 / 22
Experimental septic shock study 3 (D2; non-survivor)
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

dexamethasone study 9 (24h) / EtOH treated CCRF-CEM-C7H2 cell sample

Relative Expression (log2-ratio):1.379426
Number of Samples:3 / 3
Experimental dexamethasone study 9 (24h)
CCRF-CEM-C7H2 cells cultured in the presence of dexamethansone (10e-7M) for 24 hours. ATC code:, , , , , , , , , ,
Control EtOH treated CCRF-CEM-C7H2 cell sample
CCRF-CEM-C7H2 cells treated for 24 hours with 0.1% ethanol (EtOH) as carrier control.